Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 14/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 8/20 | 0.46 |
| ▸ | MEN1 | O00255 | 7/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 8/20 | 0.37 |
| ▸ | MAPT | P10636 | 7/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.37 |
| ▸ | ALOX15 | P16050 | 6/20 | 0.37 |
| ▸ | TP53 | P04637 | 6/20 | 0.37 |
| ▸ | HTT | P42858 | 6/20 | 0.37 |
| ▸ | NPC1 | O15118 | 5/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | GFER | P55789 | 2/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | USP2 | O75604 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | HPGD | P15428 | 4/20 | 0.33 |
| ▸ | PKM | P14618 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344851 | 1.00 | GAA (0.46) | GAAHSD17B10MEN1KMT2ARAB9A | |
| SCHEMBL3392326 | 1.00 | GAA (0.46) | GAAHSD17B10MEN1KMT2ARAB9A | |
| SCHEMBL5115588 | 0.77 | — | — | |
| SCHEMBL9170083 | 0.74 | — | — | |
| SCHEMBL41618 | 0.72 | GAA (0.53) | GAAHSD17B10MEN1KMT2ARAB9A | |
| SCHEMBL199861 | 0.72 | GAA (0.53) | GAAHSD17B10MEN1KMT2ARAB9A | |
| Benzene SCHEMBL27553763 | 0.72 | GAA (0.53) | GAAHSD17B10MEN1KMT2ARAB9A | |
| SCHEMBL41619 | 0.72 | GAA (0.53) | GAAHSD17B10MEN1KMT2ARAB9A | |
| SCHEMBL10625398 | 0.70 | GAA (0.51) | GAAHSD17B10MEN1KMT2ARAB9A | |
| Hydrochloric Acid SCHEMBL9474549 | 0.70 | GAA (0.51) | GAAHSD17B10MEN1KMT2ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 98 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451209-A4 | TETRA-,PENTA-,HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2009-06-03 | — | — | EP | claimed |
| EP-1078002-B1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LAB (US) | 2008-05-21 | — | — | EP | claimed |
| US-20080071062-A1 | TETRA-, PENTA-, HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | HAVIV FORTUNA | 2008-03-20 | — | — | US | claimed |
| EP-1461356-A4 | HEXA-, HEPTA-, AND OCTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LAB (US) | 2007-12-12 | — | — | EP | claimed |
| US-20070167376-A1 | Hexa-, Hepta-, and Octapeptides Having Antiangiogenic Activity | HAVIV FORTUNA | 2007-07-19 | — | — | US | claimed |
| US-7122625-B2 | Hexa-, hepta-, and octapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-10-17 | — | — | US | claimed |
| US-20060194737-A1 | Hepta-, octa-and nonapeptides having antiangiogenic activity | HAVIV FORTUNA | 2006-08-31 | — | — | US | claimed |
| US-7067490-B2 | Hepta-, Octa-and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES (US) | 2006-06-27 | — | — | US | claimed |
| US-20050124548-A1 | Peptide antiangiogenic drugs | HENKIN JACK (US) | 2005-06-09 | — | — | US | claimed |
| EP-1461356-A2 | HEXA-, HEPTA-, AND OCTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030109455-A1 | HEPTA-, OCTA-and nonapeptides having antiangiogenic activity | ABBVIE INC. | 2003-06-12 | — | — | US | claimed |
| US-20030105023-A1 | Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity | ABBVIE INC. | 2003-06-05 | — | — | US | claimed |
| US-20030105022-A1 | Tetra-, penta-, hexa- and heptapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-06-05 | — | — | US | claimed |
| US-20030096758-A1 | HEPTA-, OCTA- and nonapeptides having antiangiogenic activity | ABBOTT LABORATORIES | 2003-05-22 | — | — | US | claimed |
| WO-2003037268-A2 | HEPTA-, OCTA- AND NONAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-05-08 | — | — | WO | claimed |
| WO-2003037266-A2 | TETRA-, PENTA-, HEXA- AND HEPTAPEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2003-05-08 | — | — | WO | claimed |
| EP-1242455-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | Abbott Laboratories (US) | 2002-09-25 | — | — | EP | claimed |
| WO-2001038397-A1 | N-ALKYLATED PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY | ABBOTT LABORATORIES (US) | 2001-05-31 | — | — | WO | claimed |
| EP-1078002-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 2001-02-28 | — | — | EP | claimed |
| WO-1999061476-A1 | PEPTIDE ANTIANGIOGENIC DRUGS | ABBOTT LABORATORIES (US) | 1999-12-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050124548-A1 | Peptide antiangiogenic drugs | VEGFA, NPPA, FLT1 | GAA 3410/4885HSD17B10 997/4885MEN1 646/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.